Jefferies raises Disc Medicine stock price target on drug opportunity

Jefferies has increased its price target for Disc Medicine shares (NASDAQ:IRON) from $128 to $149, while maintaining a "Buy" rating. The company's stock has experienced a significant 42.6% increase over the past week due to positive clinical results. The investment firm highlighted the Phase 3 topline results for bitopertin, which is touted as the first disease-modifying drug in its medical field. Following the New Drug Application resubmission by end of 2026, Jefferies anticipates approval by mid-2027.

Disc Medicine's market capitalization is valued at $2.93 billion, and the firm estimates a patient pool of roughly 6,000 to 14,000. This patient base could potentially generate a commercial opportunity worth $1 billion to $2 billion. Jefferies anticipates presenting data and regulatory updates for its myelofibrosis anemia program and longer-term follow-up data for its polycythemia vera program before year-end 2026, possibly at the American Society of Hematology meeting.

Recent analyst updates have also reflected positively on Disc Medicine. BMO Capital increased its price target to $120 from $100, keeping an "Outperform" rating, thanks to the Phase 3 APOLLO trial results. Cantor Fitzgerald raised its price target to $170 from $125, also commending the Phase 3 results for bitopertin in the treatment of severe photosensitivity conditions.

Wells Fargo adjusted its price target to $124 from $86, emphasizing the competitive aspects of the company's data in the EPP/XLP index. Truist Securities raised its target to $115 from $83, driven by increased confidence in the regulatory outlook for bitopertin following the APOLLO trial results. Lastly, H.C. Wainwright maintained its "Buy" rating with a $120 price target, following the promising Phase 2 RESTORE-PV trial outcomes.

These developments demonstrate strong analyst backing, driven by Disc Medicine's recent clinical trial results.